Vitamin B6 metabolism in microbes and approaches for fermentative production

Rosenberg, Jonathan B.; Ischebeck, Till; Commichau, Fabian M.

doi:10.1016/j.biotechadv.2016.11.004

Cited by 65 publications

(60 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, compared with run-in, the treatment drove to an enrichment of lactococci, streptococci and total anaerobes bacteria that might be explained by the intake of vitamin B6. 34 According to Pinto-Sanchez et al, 35 the LBB treatment did not affect the alpha diversity (Shannon index) and the microbial community level catabolic profiles. Changes in faecal VOCs reflect gut disorders and inflammatory conditions of IBS patient.…”

Section: Discussionmentioning

confidence: 94%

“…Moreover, the composition of probiotic, containing a higher amount of bifidobacteria, that could be associated with the stronger increase of this microbial group, that also showed lower cell density at the beginning of the study. Interestingly, compared with run‐in, the treatment drove to an enrichment of lactococci, streptococci and total anaerobes bacteria that might be explained by the intake of vitamin B6 . According to Pinto‐Sanchez et al, the LBB treatment did not affect the alpha diversity (Shannon index) and the microbial community level catabolic profiles.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients

Bonfrate

Palo

Celano

et al. 2020

Eur J Clin Investigation

View full text Add to dashboard Cite

Background Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, which still lacks effective therapy. We aimed to investigate the effects of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6 (LBB) on symptoms, intestinal permeability, cultivable bacteria and metabolome in IBS subjects. Materials and methods Twenty‐five IBS patients (Rome IV criteria) (M:F = 8:17; age 48 years ± 11 SD) were randomized to treatment (LBB) or placebo (one month each) in a crossover randomized double‐blind controlled trial. Symptoms, intestinal habits, disease severity, intestinal permeability and intestinal microbiota were analysed at 0, 30, 45 and 60 days. Results Percentage decrease from baseline of abdominal pain (−48.8% vs −3.5%), bloating (−36.35% vs +7.35%) and severity of disease (−30.1% vs −0.4%) was significantly (P < .0001) greater with LBB than placebo, respectively. In IBS‐D patients, the improvement from baseline of Bristol score was more consistent with LBB (from 6 ± 0.4 to 4.3 ± 1.1, P < .00001) than placebo (from 6.2 ± 0.7 to 5.3 ± 1.1, P = .04). In IBS‐C patients, Bristol score tended to improve from baseline after LBB (2.6 ± 1.1 vs 3.2 ± 0.5, P = .06). LBB significantly improved the percentage of sucralose recovery (colonic permeability) (1.86 ± 0.1 vs 1.1 ± 0.2, P = .01). During treatment, presumptive lactic acid bacteria and bifidobacteria, relative abundance of propanoic, butanoic, pentanoic acids and hydrocarbons increased, while phenol decreased. Conclusions The novel formulation of B. longum BB536 and L. rhamnosus HN001 with B6 vitamin improves symptoms and severity of disease, restores intestinal permeability and gut microbiota in IBS patients.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 96%

Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients

Bonfrate

Palo

Celano

et al. 2020

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Vitamin B6 exist as six vitamers, including pyridoxine (PN), pyridoxamine (PM), pyridoxine 5′-phosphate (PNP), pyridoxamine 5′-phosphate (PMP), pyridoxal 5′-phosphate (PLP) and pyridoxal (PL) 8 . Dietary PN and PM serve as the main source of PNP and PMP.…”

Section: Introductionmentioning

confidence: 99%

Pyridoxine 5′-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer

et al. 2017

View full text Add to dashboard Cite

Pyridoxine 5′-phosphate oxidase (PNPO) is an enzyme that converts pyridoxine 5′-phosphate into pyridoxal 5′-phosphate (PLP), an active form of vitamin B6 implicated in several types of cancer. However, the role of PNPO and its regulatory mechanism in epithelial ovarian cancer (EOC) are unknown. In the present study, PNPO expression in human ovarian tumour tissue and its association with the clinicopathological features of patients with EOC were examined. Further, the biological function of PNPO in EOC cells and in xenograft was evaluated. We demonstrated for the first time that PNPO was overexpressed in human EOC. Knockdown of PNPO induced EOC cell apoptosis, arrested cell cycle at G2/M phase, decreased cell proliferation, migration and invasion. Xenografts of PNPO-shRNA-expressing cells into the nude mouse attenuated tumour growth. PNPO at mRNA and protein levels in EOC cells was decreased after transforming growth factor-β1 (TGF-β1) treatment. The inhibitory effect of TGF-β1 on PNPO expression was abolished in the presence of SB-431542, a TGF-β type I receptor kinase inhibitor. Moreover, we found that TGF-β1-mediated PNPO expression was at least in part through the upregulation of miR-143-3p. These data indicate a mechanism underlying PNPO regulation by the TGF-β signalling pathway. Furthermore, PLP administration reduced PNPO expression and decreased EOC cell proliferation, suggesting a feedback loop between PLP and PNPO. Thus, our findings reveal that PNPO can serve as a novel tissue biomarker of EOC and may be a potential target for therapeutic intervention.

show abstract

“…Finally, the postoperative complications of patients were counted, and it was found that the incidence rate of postoperative complications of patients in the control group was higher than that in the observation group, and the difference was statistically significant (p<0.05), indicating that the combination of the two drugs can reduce the incidence rate of postoperative complications. Previous findings have shown that vitamin B6 can promote the synthesis of endogenous carbon monoxide (NO) and platelet-derived NO ( 18 – 20 ). However, endogenous NO and platelet-derived NO can reduce platelet activation and platelet aggregation, thereby indicating that vitamin B6 can indirectly affect platelet activation and platelet aggregation, and reduce the occurrence of atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

Glycerol fructose combined with vitamin B6 is beneficial to postoperative recovery of patients with cerebral aneurysm

Chen

Lei

2018

Exp Ther Med

View full text Add to dashboard Cite

The aim of the present study is to investigate whether glycerol fructose combined with vitamin B6 is beneficial to the postoperative recovery of patients with cerebral aneurysm (CA). A total of 134 patients receiving embolization of CA in the Central Hospital of Wuhan between February, 2013 and June, 2015 and were divided into observation and control groups according to the random number table method, with 67 cases in each group. The control was given vitamin B6 routine treatment, while the observation group received glycerol fructose on the basis of treatment in the control group. The incidence rate of postoperative complications after treatment, Glasgow coma scale (GCS) score, Barthel index score, and neurological fatigue index (NFI) score were compared between the two groups. After treatment, the GCS, Barthel index and NFI scores of patients in the observation were better than those in the control group (p<0.05), and the Barthel index score in the observation group was significantly higher than that in the control group (p<0.01). The mean flow velocity of middle cerebral artery (MCA) in the observation group after treatment was significantly different from that in the control group (p<0.05). As for complications, the incidence rates of postoperative cerebral vasospasm (1.49%), cerebral ischemia (1.49%), hematoma at puncture site (2.98%) and aneurysm rupture and hemorrhage (4.47%) in the observation group were lower than those of cerebral vasospasm (8.95%), cerebral ischemia (7.46%), hematoma at puncture site (8.95%) and aneurysm rupture and hemorrhage (10.44%) in the control group, and the differences were statistically significant (p<0.05). In conclusion, glycerol fructose combined with vitamin B6 can reduce the incidence rate of postoperative complications and improve patients self-care ability and quality of life. Therefore, it is beneficial to postoperative recovery and it is worthy of clinical application.

show abstract

Vitamin B6 metabolism in microbes and approaches for fermentative production

Cited by 65 publications

References 131 publications

Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients

Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients

Pyridoxine 5′-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer

Glycerol fructose combined with vitamin B6 is beneficial to postoperative recovery of patients with cerebral aneurysm

Contact Info

Product

Resources

About